Omega-3 Fatty Acid Supplementation for Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Symptom Domains

Abstract

Introduction: Omega-3 polyunsaturated fatty acids (PUFAs), particularly EPA and DHA, have been proposed as a complementary treatment for attention-deficit/hyperactivity disorder (ADHD). However, meta-analyses show mixed results, possibly due to pooling across inattention and hyperactivity domains that may respond differently.

Description: Systematic review and meta-analysis of RCTs of omega-3 supplementation (≥8 weeks) in children and adolescents (4–18 years) with ADHD diagnosis or elevated symptoms. Primary outcomes: inattention and hyperactivity/impulsivity separately (teacher or parent ratings). Databases: PubMed, PsycINFO, Cochrane. Subgroup analysis by EPA:DHA ratio and baseline PUFA status.

Results: Twenty-six RCTs (n=2,211 participants) were included. Omega-3 significantly reduced inattention (SMD –0.29, 95% CI –0.41 to –0.17, p<0.001) but not hyperactivity/impulsivity (SMD –0.11, –0.23 to 0.01, p=0.07). Formulations with EPA:DHA ratio ≥1.5:1 improved inattention more (SMD –0.38) than lower ratios (–0.18). Baseline low PUFA status predicted larger effect (SMD –0.44 vs. –0.16 in normal status). No significant adverse events except mild gastrointestinal symptoms (10% vs. 6% placebo).

Discussion: Omega-3 supplementation modestly improves inattention but not hyperactivity in ADHD. Domain-specific effects suggest distinct neurobiological mechanisms: PUFAs may enhance prefrontal dopamine tone (inattention) less than striatal circuits (hyperactivity). The EPA-predominant formulation effect aligns with adult depression data. Limitations: high heterogeneity in outcome measures, short trials.

Conclusions: Omega-3 supplements (EPA-predominant) provide a small benefit for ADHD inattention, particularly in children with low baseline PUFA status. Effects are less robust than stimulants but may be considered as adjunctive or for families declining pharmacotherapy.